Статья
АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА В ПРОФИЛАКТИКЕ АТЕРОТРОМБОЗА
Результаты крупномасштабных клинических исследований убедительно показали эффективность ацетилсалициловой кислоты (АСК) в первичной и вторичной профилактике атеротромбоза. Продолжаются исследования безопасности различных лекарственных форм АСК. Гидроокись магния, входящая в комбинированный препарат Кардиомагнил, предотвращает негативное воздействие АСК на слизистую оболочку желудка и уменьшает выраженность диспептических проявлений.
1. Kosarev V .V ., Babanov S.A., Verbovoy A.F . Handbook of clinical pharmacology . Rostov-na-Donu: Feniks; 2011. Russian (Косарев В.В., Бабанов С.А., Вербовой А.Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс; 2011).
2. Lepakhin V.K., editor . Pharmacology and drug therapy. Moscow: Eksmo; 2009. Russian (Лепахин В.К., редактор. Фармакология и лекарственная терапия. М.: Эксмо; 2009).
3. Shal'nova S.A., Deev A.D., Oganov R.G. Factors influencing the mortality from cardiovascular diseases in the Russian population. Kardiovaskulyarnaya Terapiya i Profilaktika 2005; (1): 4–9. Russian (Шальнова С.А., Деев А.Д., Оганов Р .Г . Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная Терапия и Профилактика 2005; (1): 4–9).
4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349–60.
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
6. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849–60.
7. Lewis HD Jr , Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309 (7): 396–403.
8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30.
9. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159–68.
10. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117 (2): 261–95.
11. Ridker Р .М., Manson J.E., Gaziano J.M. et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114 (10): 835–9.
12. Juul-Muller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340 (8833): 1421–5.
13. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Commitee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129–35.
14. Peto R., Gray R., Collins R. et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–316.
15. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233–241.
16. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351: 1762–66.
17. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89–95.
18. Ridker P ., Cook N., Min Lee L. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13): 1293–304.
19. Montgomery PR, Berger LG, Mitenko PA, Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986; 39: 571.
20. Ridker P .M., Cook N.R., Lee I.M. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13): 1293–304.
21. Lichtenstein D., Syngal S., Wolfe M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38 (1): 5–18.
22. Karateev A.E., Nasonov E.L., Koreshkov G.G. NSAID-induced dyspepsia: prevalence and possible medical treatment. Nauchno-Prakticheskaya Revmatologiya 2003; (5): 76–78. Russian (Каратеев А.Е., Насонов Е.Л., Корешков Г .Г . НПВП-индуцированная диспепсия: распространенность и возможность медикаментозной коррекции. Научно-Практическая Ревматология 2003; (5): 76–78).
23. Awtry E.H. Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18.
24. Patrono C, Coller B, FitzGerald GA et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (S suppl): 234S–264S.
25. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J Clin Gastroenterol 1990; 12: 10–13.
26. Latini R., Cerletti C., de Gaetano G. et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int J Clin Pharmacol Ther Toxicol 1986; 24: 313–318.
27. Hawthorne A.B., Mahida Y .R., Cole A.T ., Hawkey C.J. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77–83.
28. Gantt AJ, Gantt S. Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time. Cathet Cardiovasc Diagn 1998;45(4):396–9.
29. Roderick P .J., Wilkes H.C., Meade T .W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219–226.
30. Kelly J.P ., Kaufman D.W., Jurgelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–1416.
31. Slattery D.E., Pollack C.V. Balancing Potency of Platelet Inhibition with Bleeding Risk in the Early Treatment of Acute Coronary Syndrome. West J Emerg Med 2009; 10(3): 163–175.
32. Ivashkin V.T . Place of antacids in the modern treatment of peptic ulcer . Russkiy Meditsinskiy Zhurnal 2002; 4(2) suppl: 42–46. Russian (Ивашкин В.Т . Место антацидов в современной терапии язвенной болезни. Русский Медицинский Журнал 2002; 4(2) Приложение: 42–46).
33. Schmidt C., Baumeister B., Kipnowski J. and oth. Magaldrate stimulates endogenous prostaglandin E2 synthesis in human gastric mucosa in vitro and in vivo. Hepatogastroenterology 1998; 45: 2443–6.
34. Gohary O.M., Din K., Tahir H. Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. Boll Chim Farm 1996; 135: 421–8.
35. Mach T . In vivo and vitro study of prostaglandins E2 and I2 participation in protective function of antacids on gastric mucosa. Folia Med Cracov 1992; 33: 37–51.
36. Gasbarrini G., Andreone P ., Baraldini M. et al. Protection of the upper gastrointestinal mucosa: the role of antacids. Int J Clin Pharmacol Res 1990;10: 173–8.
37. Konturek S.J., Brzozowski T ., Majka J., et al. Implications of nitric oxide in the action of cytoprotective drugs on gastric mucosa. J Clin Gastroenterol 1993; 17 Suppl 1: S140–5.
38. Muller P ., Dammann H.G., Simon B. Protective effect of two antacids in acute acetylsalicylic acid-induced injuries to the human gastric mucosa. Arzneimittelforschung 1985; 35: 1862–4.
39. Linnoila M., Lehtola J. Absorption, and effect on gastric mucosa, of buffered and non–buffered tablets of acetylsalicylic acid. Int J Clin Pharmacol Biopharm 1977; 15: 61–4.
40. Maev I.V., Samsonov A.A. The use of modern antacids in the treatment of acid disorders of the gastrointestinal tract. Spravochnik Poliklinicheskogo Vracha 2005; 3(5): 43–48. Russian (Маев И.В., Самсонов А.А. Приме-
41. нение современных антацидных средств в терапии кислотозависимых заболеваний желудочно-кишечного тракта. Справочник Поликлинического Врача 2005; 3(5): 43–48).
42. Kukes V .G., Ostroumova O.D. Cardiomagnyl. A new view of acetylsalicylic acid. A Handbook for Physicians. Moscow; 2004. Russian (Кукес В.Г ., Остроумова О.Д. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей. M.; 2004).
43. Vovk E.I., Naumov A.V., Chudakov S.Yu. An effective and safe antiplatelet therapy in general practice. Vrach Skoroy Pomoshchi 2006; (1): 51–59. Russian (Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Врач Скорой Помощи 2006; (1): 51–59).